Lycia Therapeutics
PublicLycia Therapeutics is now publicly traded
The data on this page reflects Lycia Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
Jun 25, 2026
Total Funding Raised
$301.6M
Company Overview
Lycia Therapeutics operates in Biotech and is based in South San Francisco, California. It has raised $301.6M.
Lycia Therapeutics is a biotechnology company that discovers and develops first-in-class therapeutics using a lysosomal targeting chimeras platform to degrade extracellular and membrane-bound proteins associated with challenging diseases like cancers and autoimmune conditions.
Sector
Biotech
Verticals
HealthTech, Life Sciences, Oncology
AI Layer
Non-AI
Lycia Therapeutics Comparables
Compare Lycia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 87% | |
| Avilar Therapeutics | 85% | |
| Amphista Therapeutics | 82% |
For institutional investors. Book with your work email.
Lycia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 25, 2026 | ||||
| Series C | May 13, 2024 | ||||
| Series B | Sep 9, 2021 | ||||
| Series A | Jun 9, 2020 |
For institutional investors. Book with your work email.
Lycia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series B |
| Owl Rock Capital Group | Series C |
| Janus Henderson Group | Series C, Series D |
| Balyasny Asset Management L.P. | Series D |
| Franklin Advisers | Series C |
| Franklin Templeton | Series D, Series C |
| TD Securities | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 26, 2026
In June '26, Lycia Therapeutics, Inc. receives $9M in Series D financing with participation from HBM Healthcare Investments.
- identified_as_competitor_ofOct 25, 2026
Lycia Therapeutics, Inc.'s lead drug candidate is in Phase 1 testing for food allergy and could compete against Roche's blockbuster drug Xolair, the only FDA-approved biologic option for the condition.
- receives_financingOct 24, 2026
Lycia Therapeutics, Inc. receives $318M in an upsized United States initial public offering on Oct 23rd '26.
- receives_financingOct 22, 2026
Lycia Therapeutics, Inc. hopes to raise $228M through an IPO to advance its protein degrader pipeline.
- is_developingOct 22, 2026
Lycia Therapeutics, Inc. develops LCA-0321, a protein-small molecule for Graves' disease, which is in Phase 1 testing with data expected in 2027.
For institutional investors. Book with your work email.
Lycia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.